In June 2011 CBS News reported that Actos (pioglitazone), manufactured by Takeda Pharmaceuticals used to treat patients with Type 2 diabetes, has been removed from the shelves in France and Germany. A government funded study found that Actos (pioglitazone) increased the bladder cancer risk for patients taking the drug. Read more from the CBS News Report here.
Shortly after the Actos ban in Europe, the U.S. Food and Drug Administration (FDA) released a safety announcement on June 15, 2011, raising concern over Actos and its link to bladder cancer. This announcement cites the study conducted in France which indicates prolonged usage of Actos increases a patients risk for developing bladder cancer.
If you or a loved one is experiencing any side effects after using Actos or another drug to treat Type 2 diabetes, please contact Cohen & Malad, LLP to speak with one of our experienced product liability/personal injury attorneys and discuss your legal options and help you seek the compensation you deserve.